CD4 and metabolic dysfunction-associated steatohepatitis: In NASH-driven HCC, although CCL2/CCR2 has a dual role on immune cells which can drive the infiltration of both MDSCs and CD4+ Th1, CD8+ cells (183), a pre-clinical study has demonstrated that a CCR2 antagonist which can block immunosuppression mediated by tumor-infiltrating macrophage and increase CD8+ T cells exhibits an anti-tumor role in HCC, with a more significant effect combined with low-dose sorafenib (184, 185).